Reprocessed Agilis Steerable Introducer Sheath by Sterilmed: Class I Recall — Improper seal of sheath hub.
AUDIENCE:
Risk Manager, Cardiology
ISSUE:
The Agilis Steerable Introducer Sheath’s hemostatic valve, which prevents blood from flowing back through the valve, may fail due to an improper seal of the sheath hub. Improper seals can allow blood to leak through the hub, cause the cap to fall off during the procedure, or can create a difference in pressure that allows air into the circulatory system (air embolism).
- Model numbers and lot numbers: STJ408309, STJ408310, STJG408324; All product lots
- Manufacturing and Distribution Dates: January 1, 2017 to May 5, 2017
The use of affected products may cause serious health consequences for patients, including death.
The Agilis Steerable Introducer Sheath. Credit: Sterilmed via FDA)
BACKGROUND:
The Agilis Steerable Introducer Sheath is used to insert and position various cardiovascular catheters in the heart, including on the left side of the heart through the wall of tissue that separates the right and left chambers of the heart (interatrial septum).
The improper seal occurs when not enough glue is used to reattach the cap to the hub after reprocessing. Too much glue can also block the sheath valve and make the device unusable.
RECOMMENDATION:
Sterilmed has provided the following instructions for health care facilities and providers:
- Examine inventory immediately to determine if you have this product.
- Do not use any of the affected products, and return any unused product to the company.
- Share this information with the appropriate staff at your facility.
- Continue to monitor patients treated with the Sterilmed Reprocessed Agilis Steerable Introducer Sheath as normal.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.
Click here to read the MedWatch safety alert, along with a link to the press release.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
(Source: FDA MedWatch)
